Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies

NCT02169791 is registered in ClinicalTrials.gov with Northside Hospital, Inc. as lead sponsor.

NCT NCT02169791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02169791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies
Lead sponsor
Northside Hospital, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2014
Completion date
July 28, 2020
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, chronic leukemia, lymphomas, multiple myeloma, myelodysplastic syndrome